Sequence: CKRRMKWKK
| Experiment Id | EXP001183 |
|---|---|
| Paper | Co-delivery of CPP decorated doxorubicin and CPP decorated siRNA by NGR-modified nanobubbles for imp |
| Peptide | CPP |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | CPP–siRNA (and CPP–DOX) within NBs |
| Rna Concentration | 1.2 mg/kg siRNA (in vivo dose) |
| Mixing Ratio | |
| Formulation Format | CPP–DOX + CPP–siRNA/NB with ultrasound (+US) |
| Formulation Components | NBs (HSPC:DSPE:DSPE-PEG2000) co-loaded with CPP–DOX and CPP–siRNA; perfluorobutane gas core; US-triggered release |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Male nude mice bearing subcutaneous HT-1080 tumors (~200 mm^3 pre-treatment) |
| Administration Route | Tail vein injection every 3 days; +US groups: tumor sonication 30 min post-injection (1 MHz, 1 W/cm^2, 10 s on/10 s off, total 60 s) |
| Output Type | In vivo therapeutic effect (tumor growth inhibition) |
| Output Value | Tumor growth inhibition stronger than free DOX+siRNA |
| Output Units | |
| Output Notes | Co-delivery + US improved antitumor efficacy. |
| Toxicity Notes | |
| Curation Notes |